financetom
Business
financetom
/
Business
/
oilfield services provider Oceaneering beats Q3 revenue estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
oilfield services provider Oceaneering beats Q3 revenue estimates
Oct 22, 2025 2:21 PM

Overview

* Oceaneering Q3 2025 revenue grows 9% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 2025 beats consensus, reflecting solid segment performance

* Company repurchased 440,814 shares for $10.1 mln, indicating confidence in future prospects

Outlook

* Company projects Q4 2025 EBITDA between $80 mln and $90 mln

* Oceaneering ( OII ) forecasts 2026 EBITDA between $390 mln and $440 mln

* Company expects 2026 free cash flow to match 2025 levels

Result Drivers

* MANUFACTURED PRODUCTS - Higher-margin backlog conversion drove improved operating income and margin expansion

* OFFSHORE PROJECTS - Favorable project mix and steady vessel utilization supported segment performance

* SUBSEA ROBOTICS - Increased ROV revenue per day utilized despite flat revenue and operating income

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $743 mln $712.48

Revenue mln (3

Analysts

)

Q3 Beat $0.55 $0.42 (4

Adjusted Analysts

EPS )

Q3 EPS $0.71

Q3 Net $71.30

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the oil related services and equipment peer group is "buy."

* Wall Street's median 12-month price target for Oceaneering International Inc ( OII ) is $23.50, about 0.6% below its October 21 closing price of $23.64

* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CBL & Associates Properties Buys Back $12.5 Million Block of Shares
CBL & Associates Properties Buys Back $12.5 Million Block of Shares
Oct 10, 2024
04:53 PM EDT, 10/10/2024 (MT Newswires) -- CBL & Associates Properties ( CBL ) repurchased 500,000 shares for $12.5 million in a privately negotiated block trade with a single investor. The trade wasn't part of an existing repurchase program, CBL said Thursday in a statement. The company said it completed the share buyback program of up to $25 million on...
Allakos Subcutaneous Therapy for Mast Cells-Related Diseases 'Well-Tolerated;' Shares Up After Hours
Allakos Subcutaneous Therapy for Mast Cells-Related Diseases 'Well-Tolerated;' Shares Up After Hours
Oct 10, 2024
04:55 PM EDT, 10/10/2024 (MT Newswires) -- Allakos ( ALLK ) said Thursday results of a phase 1 trial showed that a subcutaneously administered AK006, its investigational monoclonal antibody that selectively inhibits mast cells, was well-tolerated with a favorable safety profile. The company reported data from single dose subcutaneous AK006 up to 720 milligrams, with skin biopsies taken from treated...
BRIEF-Millennium Management Reports 5.7%Passive Stake In Frontview REIT As Of Oct 4- SEC Filing
BRIEF-Millennium Management Reports 5.7%Passive Stake In Frontview REIT As Of Oct 4- SEC Filing
Oct 10, 2024
FrontView REIT Inc ( FVR ): * MILLENNIUM MANAGEMENT REPORTS 5.7%PASSIVE STAKE IN FRONTVIEW REIT AS OF OCT 4- SEC FILING Source text for Eikon: Further company coverage: ...
Heron Therapeutics Reaffirms Supply of Ready-to-Administer Nausea Prevention Medications
Heron Therapeutics Reaffirms Supply of Ready-to-Administer Nausea Prevention Medications
Oct 10, 2024
04:53 PM EDT, 10/10/2024 (MT Newswires) -- Heron Therapeutics ( HRTX ) said Thursday it can continue supplying its ready-to-administer chemotherapy-induced and postoperative nausea and vomit prevention medications Cinvanti, Sustol, and Aponvie amid the expected shortage of intravenous fluids caused by Hurricane Helene. The expected disruption in IV fluid supply is due to the temporary closure of a major manufacturing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved